

## ASX Announcement

### **VAXINIA selected for Oral and Poster Presentations at 2024 Cholangiocarcinoma Foundation Annual Conference**

---

**Sydney, Australia, 3 April 2024:** Imugene Limited (ASX: IMU), a clinical stage immuno-Oncology company, is pleased to announce that its CF33-hNIS (VAXINIA) technology has been selected for a short oral presentation during the Basic Science Research Seminar Abstract Session at 12:15 pm on Thursday April 18<sup>th</sup> at the 2024 Cholangiocarcinoma Foundation Annual Conference. Imugene will also be presenting a poster during the poster session.

The abstract, titled ‘CF33-hNIS, a novel oncolytic virus for the treatment of cholangiocarcinoma and biliary tract malignancies,’ concludes that CF33-hNIS monotherapy may be an effective and safe treatment option for GI malignancies, including cholangiocarcinoma, a rare disease with an unmet medical need.

The Cholangiocarcinoma Foundation Annual Conference is dedicated to advancing the understanding and treatment of cholangiocarcinoma (bile duct cancer). The 2024 edition, marking the 11th annual conference, is scheduled for 17-19 April 2024 at the Salt Palace Convention Center in Salt Lake City, Utah. This conference brings together a wide array of participants, including medical professionals, researchers, patients, and caregivers, creating a unique platform for sharing the latest advancements in research, clinical trials, and patient care.

Cholangiocarcinoma is a rare and aggressive form of cancer that occurs in the bile ducts, which are the slender tubes that carry the digestive fluid bile from the liver to the small intestine. Early detection is challenging, and because of its aggressiveness, the prognosis for cholangiocarcinoma can be poor, making research and advancements in treatment essential.



For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
info@imugene.com

**Investor Enquiries**  
shareholderenquiries@imugene.com

**Media Enquiries**  
Matt Wright  
matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited  
Follow us on Twitter @TeamImugene  
Watch us on YouTube @ImugeneLimited  
Join us on InvestorHub; [investorhub.imugene.com](https://investorhub.imugene.com)

### **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and



resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.*